Bausch Health and Salix in Collaboration With Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Bausch Health and Salix in Collaboration With Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
LAVAL, Quebec, December 5, 2024 - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC.
加拿大拉瓦尔,2024年12月5日 - Bausch Health公司(纽交所:BHC)(TSX:BHC)及其胃肠病(GI)业务Salix Pharmaceuticals("Salix"),与美国疼痛基金会(USPF)、国际胃肠疾病基金会(IFFGD)和美国慢性疼痛协会(ACPA)联合宣布今天,即2024年12月5日为第二届阿片类药物引起的便秘(OIC)意识日。这个重要的日子旨在提高人们对阿片类药物常被忽视的副作用的认识。通过提高意识和促进开放对话,OIC意识日旨在减少围绕该控件的污名,并为受到OIC影响的众多患者提供支持。
"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."
ACPA首席执行官凯西·萨普(Kathy Sapp)表示:“作为一个致力于支持生活在疼痛控件下的人群的组织,我们自豪地参加今年的OIC意识日。通过提高意识和改善医疗提供者、患者和看护者之间的沟通,我们可以为那些受这一常见控件影响的人们带来有意义的改变。”
In 2021, about 21% of adults in the U.S. experienced chronic pain. In 2019, 22% of adults with chronic pain were treated with a prescription opioid in the past three months. Opioids can cause OIC, which is a common side effect of opioid treatment. The annual recognition of OIC Awareness Day provides a platform for patients, caregivers, and healthcare providers to discuss this condition and encourage them to join the #OICAwarenessDay movement.
在2021年,约21%的美国成人经历了慢性疼痛。在2019年,22%的慢性疼痛成人在过去三个月内接受了处方阿片类药物治疗。阿片类药物可能会导致OIC,这是阿片类治疗的常见副作用。OIC意识日的年度认可为患者、看护者和医疗提供者提供了一个平台,让他们能够讨论这一控件,并鼓励他们加入#OIC意识日运动。
"We're deeply committed to bringing attention to those affected by OIC on this annual awareness day," said Ceciel Rooker, President and Executive Director of IFFGD. "Empowering patients to speak openly about their symptoms is crucial. It's the first step toward helping to ensure they receive the appropriate treatment, and not suffer in silence."
“我们深切致力于在这个年度意识日关注受到OIC影响的人们,”IFFGD主席兼执行董事塞西尔·鲁克表示。“赋权患者公开谈论他们的症状至关重要。这是确保他们接受适当治疗的第一步,而不是默默承受。”
In honor of the second annual OIC Awareness Day, Salix has refreshed the OICAwarenessDay.com website to offer valuable information and resources for healthcare providers, patients, and caregivers, addressing the causes, symptoms, and management of OIC. Additionally, Salix has partnered with influencers to spread the word online using the hashtag #vOICesOfOIC, launched a content program with Chronicon, a global community for people with chronic illnesses, and shared posts across their social media channels to increase awareness about OIC.
为了纪念第二届OIC意识日,Salix已更新OICAwarenessDay.com网站,以提供有价值的信息和资源,供医疗提供者、患者和看护者使用,内容涵盖OIC的原因、症状和管理。此外,Salix还与影响者合作,在网上通过#vOICesOfOIC的标签传播信息,推出了与Chronicon的内容项目,Chronicon是一个针对慢性疾病患者的全球社区,并在其社交媒体渠道上分享帖子,以提高对OIC的认识。
"We're honored to be a part of OIC Awareness Day for the second year in a row," said Nicole Hemmenway, CEO of USPF. "By continuing to raise awareness about this condition, we aim to educate both healthcare providers and patients about OIC, a commonly overlooked side effect."
"我们很荣幸连续第二年参与OIC宣传日,"美国疼痛基金会的首席执行官Nicole Hemmenway说道。"通过继续提高大家对这种控件的认识,我们的目标是教育医疗保健提供者和患者了解OIC这一常被忽视的副作用。"
For more information on OIC and to learn how you can join the #OICAwarenessDay movement, please visit .
有关OIC的更多信息,以及了解如何加入#OICAwarenessDay运动,请访问。
About Bausch Health
关于Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit and connect with us on LinkedIn.
Bausch Health Companies Inc.(纽交所/TSX:BHC)是一家全球多元化药品公司,通过不懈努力改善医疗保健成果,丰富人们的生活。我们主要在胃肠病学、肝脏病学、神经学、皮肤病学、国际药品和眼科健康领域开发、生产和销售一系列产品,通过我们对Bausch + Lomb Corporation的控股。我们的雄心是成为一家全球综合医疗保健公司,受患者、医疗保健专业人员、员工和投资者信任和重视。我们的胃肠科业务Salix Pharmaceuticals是全球最大的专业药品业务之一,超过30年来,我们已为治疗胃肠疾病许可、开发和营销创新产品。有关Salix的更多信息,请访问并在Twitter和LinkedIn上与我们联系。有关Bausch Health的更多信息,请访问并在LinkedIn与我们联系。
About The U.S. Pain Foundation
关于美国疼痛基金会
The U.S. Pain Foundation is a 501(c)(3) nonprofit with a mission to empower, educate, connect, and advocate for individuals living with chronic illnesses and serious injuries that cause pain, as well as their care partners and clinicians. Through its multiple programs and services, the organization works to elevate the patient voice, increase disease-state education, improve pain care through policy change, expand outreach to underserved and marginalized communities, and provide comprehensive resources to ensure individuals are supported and empowered along their journeys. Learn more at uspainfoundation.org.
美国疼痛基金会是一个501(c)(3)非营利组织,旨在赋权、教育、连接和倡导与慢性疾病和导致疼痛的严重伤害作斗争的个人,以及他们的照护伙伴和临床医生。通过多个项目和服务,该组织致力于提升患者声音、增加疾病状态教育、通过政策变革改善疼痛护理、扩大对服务不足和边缘化社区的 Outreach,并提供全面资源,确保个人在其旅程中得到支持和赋权。了解更多信息请访问uspainfoundation.org。
About The International Foundation for Gastrointestinal Disorders
关于国际胃肠疾病基金会
The International Foundation for Gastrointestinal Disorders (IFFGD) is a nonprofit education and research organization dedicated to improving the lives of people affected by chronic gastrointestinal illnesses. Founded in 1991, IFFGD helps improve patient outcomes by enhancing awareness, improving education, and supporting and encouraging research into treatments and cures for chronic digestive disorders.
国际胃肠疾病基金会(IFFGD)是一个非营利的教育和研究组织,致力于改善受慢性胃肠疾病影响的人的生活。成立于1991年,IFFGD通过提高意识、改善教育,以及支持和鼓励对慢性消化障碍的治疗和疗法进行研究,帮助改善患者的结果。
About The American Chronic Pain Association
关于美国慢性疼痛协会
The American Chronic Pain Association (ACPA) is a non-profit, 501(c) (3) organization. Our Mission is to facilitate peer support, education, hope, and motivation for individuals living with pain and those treating pain conditions. We strive to raise awareness among the health care community, policymakers, and the public at large about issues of living with physical and emotional pain. Our vision is to motivate those with pain conditions to seek quality care, to optimize healthcare office visits, and to prevent chronic disease.
美国慢性疼痛协会(ACPA)是一个非营利的501(c)(3)组织。我们的使命是为生活在疼痛中的个人及那些治疗疼痛的专业人士提供同伴支持、教育、希望和动力。我们努力在医疗保健社区、政策制定者和公众中提高关于生活在身体和情感痛苦中的问题的意识。我们的愿景是激励那些有疼痛病症的人寻求优质护理,优化医疗办公室的就诊,并预防慢性疾病。
Forward-looking Statements
前瞻性声明
This news release may contain forward-looking statements about the future performance of Bausch Health which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
本新闻稿可能包含关于Bausch Health未来业绩的前瞻性声明,这些声明通常可通过使用"预期"、"希望"、"期待"、"打算"、"计划"、"应该"、"可能"、"会"、"也许"、"相信"、"受限于"及其变体或类似表达来识别。 这些声明基于管理层当前的期望和信念,并且受到各种风险和不确定性的影响,这可能导致实际结果与前瞻性声明中描述的结果有实质性差异。 实际结果还受到与Bausch Health整体业务相关的其他风险和不确定性的影响,包括在Bausch Health最近的10-K表格年度报告中更完整描述的风险和不确定性,并不时在Bausch Health向美国证券交易委员会和加拿大证券管理局提交的其他文件中详细阐述,相关因素在此引用。
Investor Contact: | Media Contact: |
Garen Sarafian ir@bauschhealth.com (877) 281-6642(toll-free) |
Katie Savastano corporate.communications@bauschhealth.com (908) 541-3785 |
投资者联系人: | 媒体联系人: |
加伦·萨拉菲安 ir@bauschhealth.com (877) 281-6642(免电话费) |
凯蒂·萨瓦斯坦诺 corporate.communications@bauschhealth.com (908) 541-3785 |